Mrs. Lucille G Weiss, MFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1489 Baltimore Pike, Suite 250, Springfield, PA 19064 Phone: 610-544-2110 Fax: 610-604-9510 |
Dr. Nancy Mccelvey Lydick, PH.D., L.M.F.T. Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1489 Baltimore Pike Ste 200, Springfield, PA 19064 Phone: 610-544-2110 Fax: 610-604-9510 |
David Seth Trebich, M.A. Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1489 Baltimore Pike, Suite 250, Springfield, PA 19064 Phone: 610-544-2110 |
Ms. Caroline Louise Lenel, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1489 Baltimore Pike, Building 200 Suite 250, Springfield, PA 19064 Phone: 610-544-2110 |
Susan Marie Stabler Haas, LMFT, MSN, RN,CS Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1489 Baltimore Pike, Suite 250, Springfield, PA 19064 Phone: 610-544-2110 |
Mark Fred Tulin, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1489 Baltimore Pike Ste 250, Springfield, PA 19064 Phone: 610-544-2110 Fax: 610-604-9510 |
News Archive
Diabetes experts at a meeting convened by the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) took the next step in advancing efforts toward the development of an artificial pancreas: putting forth clinical recommendations to ensure the safe and effective testing of artificial pancreas technology in real-life situations.
The effort to vaccinate some of the country's most vulnerable residents against covid-19 has been slowed by a federal program that sends retail pharmacists into nursing homes — accompanied by layers of bureaucracy and logistical snafus.
Patty Bausch isn't a Medicaid expert, lawyer or medical professional. But she still thinks Connecticut legislators need her input when they consider bills affecting people like her — the roughly 18,000 residents who live in the state's nursing homes.
ADVENTRX Pharmaceuticals, Inc. announced today that it received a refuse to file letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion). In the letter, the FDA indicated that the data included in the initial submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. FDA identified only the one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX plans to meet with the FDA as soon as possible to discuss its response.
New results from a large retrospective study of the National Cancer Institute's SEER database show that patients with cancer who were married at the time of diagnosis live markedly longer compared to unmarried patients.
› Verified 8 days ago